Evaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Latest Information Update: 30 Jan 2024
At a glance
- Drugs Mitapivat (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- 12 Dec 2023 Results (at data cut off March 23, 2023) assessing the changes in the metabolome, lipidome and proteome of RBCs from patients with SCD presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results (data cutoff March 23, 2023) evaluating the safety, tolerability and efficacy of mitapivat as a long-term maintenance therapy for pts with SCD, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 21 Apr 2023 Planned End Date changed from 19 Oct 2023 to 28 Feb 2028.